1. HBW Insight
  2. >>Wellness
  3. >>Business

Amarin Says REDUCE-IT Results Are Off Limits To Omega-3 Supplement Claims

 
• By Malcolm Spicer

REDUCE-IT results are limited to Amarin's Vascepa "and cannot be extrapolated to omega-3 products that are materially different based on, for example, composition, dosage, and regulatory status," pharma firm says in complaints against Coromega and Omax. Amarin seeks to stifle the omega-3 supplement firms despite First Amendment argument it made in successful litigation against FDA to make truthful statements about its products even though the information is not approved by the agency.

Cardiovascular benefits Amarin Corp. PLC recently reported for its prescription triglyceride-lowering fish oil from the REDUCE-IT trial were so encouraging that two omega-3 dietary supplement marketers couldn't resist linking their own products to them. Hands off, Amarin effectively declares in complaints seeking to block such actions.

Amarin's response to advertising by Coromega Health Inc. and Omax Health Inc. reflects typical pharma industry interest in protecting research and development investments

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Marketing & Advertising

More from Business